Skip to content
Trial Eligibility
Menu

Psilocybin-Assisted Therapy as a Treatment for Depression

NCT07582120

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common. Novel treatments are needed that act rapidly, produce lasting effects and work differently than existing antidepressants. In clinical trials, psilocybin has shown promise as a treatment for depression due to its rapid onset of antidepressant effects and sustained benefits.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Depression

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
Washington University School of Medicine
Last updated on ClinicalTrials.gov
November 17, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Missouri · 1

  • Washington University School of Medicine · St Louis, MO

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.